Takeda Pharmaceutical (TAK) Short Interest Ratio & Short Volume $15.02 -0.05 (-0.33%) Closing price 07/8/2025 03:59 PM EasternExtended Trading$14.95 -0.07 (-0.46%) As of 04:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Takeda Pharmaceutical Short Interest DataTakeda Pharmaceutical (TAK) has a short interest of 6.50 million shares, representing 0.21% of the float (the number of shares available for trading by the public). This marks a 4.17% increase in short interest from the previous month. The short interest ratio (days to cover) is 3.0, indicating that it would take 3.0 days of the average trading volume of 1.98 million shares to cover all short positions.Current Short Interest6,500,000 sharesPrevious Short Interest6,240,000 sharesChange Vs. Previous Month+4.17%Dollar Volume Sold Short$98.80 millionShort Interest Ratio3.0 Days to CoverLast Record DateJune 15, 2025Outstanding Shares3,181,920,000 sharesShort Percent of Float0.21%Today's Trading Volume2,113,055 sharesAverage Trading Volume1,981,468 sharesToday's Volume Vs. Average107% Short Selling Takeda Pharmaceutical? Sign up to receive the latest short interest report for Takeda Pharmaceutical and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartTAK Short Interest Over TimeTAK Days to Cover Over TimeTAK Percentage of Float Shorted Over Time Takeda Pharmaceutical Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20256,500,000 shares $98.80 million +4.2%0.2%3 $15.20 5/31/20256,240,000 shares $93.66 million No Change0.2%3 $15.01 5/15/20256,240,000 shares $87.30 million +33.3%0.2%3 $13.99 4/30/20254,680,000 shares $71.51 million -6.2%0.2%2.4 $15.28 4/15/20254,990,000 shares $72.58 million -0.8%0.2%2.6 $14.55 3/31/20255,030,000 shares $74.82 million +13.3%0.2%2.5 $14.88 3/15/20254,440,000 shares $66.67 million +3.0%0.1%2.6 $15.02 2/28/20254,310,000 shares $62.06 million +4.4%0.1%2.5 $14.40 2/15/20254,130,000 shares $55.90 million +10.4%0.1%2.3 $13.54 1/31/20253,740,000 shares $50.13 million +0.8%N/A2 $13.41 Get the Latest News and Ratings for TAK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 1/15/20253,710,000 shares $48.71 million -24.4%N/A2.2 $13.13 12/31/20244,910,000 shares $65.01 million +9.8%N/A2.9 $13.24 12/15/20244,470,000 shares $59.99 million -9.2%N/A2.6 $13.42 11/30/20244,920,000 shares $67.01 million -13.1%N/A2.8 $13.62 11/15/20245,660,000 shares $77.09 million -6.1%N/A3.3 $13.62 10/31/20246,030,000 shares $84.12 million -17.4%N/A3.7 $13.95 10/15/20247,300,000 shares $102.53 million -13.3%N/A3.4 $14.05 9/30/20248,420,000 shares $119.65 million +0.4%N/A3.7 $14.21 9/15/20248,390,000 shares $123.33 million +1.9%0.3%4 $14.70 8/31/20248,230,000 shares $122.54 million +28.0%0.3%3.9 $14.89 8/15/20246,430,000 shares $92.85 million +1.9%0.2%3 $14.44 7/31/20246,310,000 shares $87.71 million -2.2%0.2%3 $13.90 7/15/20246,450,000 shares $86.37 million -9.5%0.2%4 $13.39 6/30/20247,130,000 shares $92.26 million -6.3%0.2%4.7 $12.94 6/15/20247,610,000 shares $99.69 million +15.8%0.2%4.7 $13.10 5/31/20246,570,000 shares $87.71 million +1.2%0.2%4.2 $13.35 5/15/20246,490,000 shares $86.90 million +3.3%0.2%4 $13.39 4/30/20246,280,000 shares $82.17 million +5.2%0.2%3.8 $13.09 4/15/20245,970,000 shares $78.71 million -26.5%0.2%3.2 $13.19 3/31/20248,120,000 shares $112.79 million +47.6%0.3%4.4 $13.89 3/15/20245,500,000 shares $79.70 million -12.1%0.2%3.1 $14.49 2/29/20246,260,000 shares $91.36 million -21.7%0.2%3.3 $14.60 2/15/20247,990,000 shares $115.14 million +6.0%0.3%4.2 $14.41 1/31/20247,540,000 shares $110.01 million -11.7%0.2%4.1 $14.59 1/15/20248,540,000 shares $128.44 million +8.4%0.3%4.6 $15.04 12/31/20237,880,000 shares $112.45 million -4.3%0.3%4.3 $14.27 12/15/20238,230,000 shares $112.75 million -8.4%0.3%4.3 $13.70 11/30/20238,980,000 shares $127.02 million +9.1%0.3%4.9 $14.15 11/15/20238,230,000 shares $112.59 million -5.5%0.3%4.5 $13.68 10/31/20238,710,000 shares $118.41 million -7.9%0.3%4.6 $13.60I was wrong about Trump (Ad)I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.Let me show you exactly what we’re doing to prepare. 10/15/20239,460,000 shares $143.22 million +13.0%0.3%4.7 $15.14 9/30/20238,370,000 shares $129.48 million -15.7%0.3%3.7 $15.47 9/15/20239,930,000 shares $162.16 million +53.5%0.3%4.8 $16.33 8/31/20236,470,000 shares $99.61 million -6.0%0.2%3.1 $15.40 8/15/20236,880,000 shares $104.68 million -5.1%0.2%3.2 $15.22 7/31/20237,250,000 shares $110.60 million -11.0%0.2%3.2 $15.26 7/15/20238,150,000 shares $125.35 million -9.3%0.3%4.1 $15.38 6/30/20238,990,000 shares $141.19 million +5.8%0.3%4.7 $15.71 6/15/20238,500,000 shares $137.28 million +7.2%0.3%4.1 $16.15 5/31/20237,930,000 shares $125.57 million +38.2%0.3%3.5 $15.84 5/15/20235,740,000 shares $94.82 million -1.0%0.2%2.4 $16.52 4/30/20235,800,000 shares $96.22 million +3.2%0.2%2.5 $16.59 4/15/20235,620,000 shares $94.47 million -21.4%0.2%2.3 $16.81 3/31/20237,150,000 shares $117.83 million +7.7%0.2%2.6 $16.48 3/15/20236,640,000 shares $106.77 million +32.0%0.2%2.4 $16.08 2/28/20235,030,000 shares $77.21 million -4.7%0.2%1.8 $15.35 2/15/20235,280,000 shares $82.68 million -14.3%0.2%1.9 $15.66 1/31/20236,160,000 shares $97.33 million -29.4%0.2%2.2 $15.80 1/15/20238,730,000 shares $140.55 million +19.3%0.3%3 $16.10 12/30/20227,320,000 shares $114.19 million +1.5%0.2%2.3 $15.60 12/15/20227,210,000 shares $109.16 million +24.3%0.2%2.3 $15.14 11/30/20225,800,000 shares $85.43 million +4.5%0.2%1.9 $14.73 11/15/20225,550,000 shares $76.31 million +39.1%0.2%1.8 $13.75 10/31/20223,990,000 shares $52.75 million -36.9%0.1%1.4 $13.22 10/15/20226,320,000 shares $81.34 million +32.5%0.2%2.2 $12.87 9/30/20224,770,000 shares $61.87 million +38.7%0.2%1.8 $12.97 9/15/20223,440,000 shares $46.13 million +14.3%0.1%1.4 $13.41 8/31/20223,010,000 shares $41.39 million -5.9%0.1%1.2 $13.75 8/15/20223,200,000 shares $45.57 million -12.1%0.1%1.3 $14.24 7/31/20223,640,000 shares $53.18 million -12.9%0.1%1.3 $14.61 7/15/20224,180,000 shares $60.53 million +27.1%0.1%1.6 $14.48 6/30/20223,290,000 shares $46.19 million -19.0%0.1%1.3 $14.04 6/15/20224,060,000 shares $53.96 million -14.4%0.1%1.5 $13.29 5/31/20224,740,000 shares $68.30 million -10.6%0.2%1.9 $14.41 5/15/20225,300,000 shares $76.06 million -0.2%0.2%2.1 $14.35 4/30/20225,310,000 shares $77.21 million -10.2%0.2%2.2 $14.54 4/15/20225,910,000 shares $88.12 million +32.8%0.2%2.3 $14.91 3/31/20224,450,000 shares $63.72 million -19.8%0.1%1.5 $14.32 3/15/20225,550,000 shares $80.42 million -8.9%0.2%2 $14.49 2/28/20226,090,000 shares $92.57 million -6.7%0.2%2.2 $15.20 2/15/20226,530,000 shares $99.19 million +7.9%0.2%2.3 $15.19 1/31/20226,050,000 shares $87.48 million -20.2%0.2%2.1 $14.46 1/15/20227,580,000 shares $111.81 million -4.1%0.2%2.7 $14.75 12/31/20217,900,000 shares $107.68 million -8.1%0.3%3.1 $13.63 12/15/20218,600,000 shares $117.13 million +7.5%0.3%3.2 $13.62 11/30/20218,000,000 shares $106.80 million +2.4%0.3%3.1 $13.35 11/15/20217,810,000 shares $112.54 million -16.7%0.3%3.3 $14.41 10/29/20219,370,000 shares $131.37 million +11.6%0.3%4.2 $14.02 10/15/20218,400,000 shares $118.44 million +29.0%0.3%3.8 $14.10 9/30/20216,510,000 shares $106.63 million +4.3%0.2%3.2 $16.38I was wrong about Trump (Ad)I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.Let me show you exactly what we’re doing to prepare. 9/15/20216,240,000 shares $106.08 million +7.4%0.2%3.7 $17.00 8/31/20215,810,000 shares $96.39 million +28.3%0.2%3.2 $16.59 8/13/20214,530,000 shares $75.88 million -1.7%0.1%2.4 $16.75 7/30/20214,610,000 shares $76.07 million -23.3%0.2%2.3 $16.50 7/15/20216,010,000 shares $102.29 million -36.1%0.2%3 $17.02 6/30/20219,410,000 shares $158.37 million +66.6%0.3%4.4 $16.83 6/15/20215,650,000 shares $97.24 million +2.0%0.2%2.3 $17.21 5/28/20215,540,000 shares $94.68 million -9.3%0.2%2.3 $17.09 5/14/20216,110,000 shares $103.50 million -16.8%0.2%2.3 $16.94 4/30/20217,340,000 shares $122.50 million -33.7%0.2%2.5 $16.69 4/15/202111,070,000 shares $188.85 million +17.6%0.4%2.9 $17.06 3/31/20219,410,000 shares $172.67 million +11.8%0.3%2.3 $18.35 3/15/20218,420,000 shares $155.26 million +28.2%0.3%2.2 $18.44 2/26/20216,570,000 shares $110.05 million +11.7%0.2%1.8 $16.75 2/12/20215,880,000 shares $103.08 million -5.0%0.2%1.8 $17.53 1/29/20216,190,000 shares $111.11 million -20.3%0.2%2.1 $17.95 1/15/20217,770,000 shares $139.08 million +2.4%0.3%3.1 $17.90 12/31/20207,590,000 shares $137.99 million -3.4%0.2%4.7 $18.18 12/15/20207,860,000 shares $148.08 million +19.6%0.3%5.8 $18.84 11/30/20206,570,000 shares $118.06 million +3.5%0.2%5.4 $17.97 11/15/20206,350,000 shares $109.79 million +22.8%0.2%5.4 $17.29 10/30/20205,170,000 shares $82.46 million +37.9%0.2%4.5 $15.95 10/15/20203,750,000 shares $65.36 million +7.1%0.1%3.4 $17.43 9/30/20203,500,000 shares $62.44 million +53.5%0.1%3.3 $17.84 9/15/20202,280,000 shares $42.00 million -18.0%0.1%2.3 $18.42 8/31/20202,780,000 shares $51.74 million +2.2%0.1%2.6 $18.61 8/14/20202,720,000 shares $50.29 million -0.4%0.1%2.5 $18.49 7/31/20202,730,000 shares $49.69 million +34.5%0.1%2.4 $18.20 7/15/20202,030,000 shares $35.18 million -2.9%0.1%1.8 $17.33 TAK Short Interest - Frequently Asked Questions What is Takeda Pharmaceutical's current short interest? Short interest is the volume of Takeda Pharmaceutical shares that have been sold short but have not yet been closed out or covered. As of June 15th, investors have sold 6,500,000 shares of TAK short. 0.21% of Takeda Pharmaceutical's shares are currently sold short. Learn More on Takeda Pharmaceutical's current short interest. What is a good short interest ratio for Takeda Pharmaceutical? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TAK shares currently have a short interest ratio of 3.0. Learn More on Takeda Pharmaceutical's short interest ratio. Which institutional investors are shorting Takeda Pharmaceutical? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Takeda Pharmaceutical: Walleye Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Takeda Pharmaceutical? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.21% of Takeda Pharmaceutical's floating shares are currently sold short. Is Takeda Pharmaceutical's short interest increasing or decreasing? Takeda Pharmaceutical saw a increase in short interest in June. As of June 15th, there was short interest totaling 6,500,000 shares, an increase of 4.2% from the previous total of 6,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Takeda Pharmaceutical's short interest compare to its competitors? 0.21% of Takeda Pharmaceutical's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Takeda Pharmaceutical: Sanofi (0.18%), GSK PLC Sponsored ADR (0.82%), argenex SE (3.39%), BioNTech SE Sponsored ADR (2.58%), Teva Pharmaceutical Industries Ltd. (3.50%), Insmed, Inc. (6.33%), Summit Therapeutics PLC (27.22%), Intra-Cellular Therapies, Inc. (2.58%), Genmab A/S Sponsored ADR (0.36%), Dr. Reddy's Laboratories Ltd (1.52%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Takeda Pharmaceutical stock? Short selling TAK is an investing strategy that aims to generate trading profit from Takeda Pharmaceutical as its price is falling. TAK shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Takeda Pharmaceutical? A short squeeze for Takeda Pharmaceutical occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TAK, which in turn drives the price of the stock up even further. How often is Takeda Pharmaceutical's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TAK, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies Sanofi Short Squeeze GSK Short Squeeze argenex Short Squeeze BioNTech Short Squeeze Teva Pharmaceutical Industries Short Squeeze Insmed Short Squeeze Summit Therapeutics Short Squeeze Intra-Cellular Therapies Short Squeeze Genmab A/S Short Squeeze Dr. Reddy's Laboratories Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:TAK) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TAK Stock Alerts